Meeting
2023 ASCO Annual Meeting
Safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of AZD2936, a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-experienced advanced/metastatic non-small-cell lung cancer (NSCLC): First report of ARTEMIDE-01.
Authors
Kristoffer Staal Rohrberg
University Hospital of Copenhagen, Copenhagen, Denmark
Kristoffer Staal Rohrberg , Mariana Brandão , Eduardo Castanon Alvarez , Enriqueta Felip , Eelke Hiddo Gort , T.Jeroen Jeroen Nicolaas Hiltermann , Hiroki Izumi , Dong-Wan Kim , Sang-We Kim , Luis G. Paz-Ares , Benjamin J. Solomon , Laurie Steinbusch , Els Wauters , Tatsuya Yoshida , Huifang Chen , Andrew Goldwin , Yu Jiang , Ikbel Achour , Moritz Wolfgang Drachsler , Byoung Chul Cho
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT04995523
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9050)
DOI
10.1200/JCO.2023.41.16_suppl.9050
Abstract #
9050
Poster Bd #
38
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
AdvanTIG-206: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (BGB-A1217; OCI) plus anti-programmed cell death protein 1 (PD-1) mAb tislelizumab (TIS) plus BAT1706 versus (vs) TIS plus BAT1706 as first-line treatment for advanced hepatocellular carcinoma (HCC).
First Author: Jia Fan
Poster
2021 ASCO Annual Meeting
Preliminary safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of uliledlimab (TJ004309), a differentiated CD73 antibody, in combination with atezolizumab in patients with advanced cancer.
First Author: Francisco Robert
Poster
2023 ASCO Annual Meeting
Exploring the potential of combination immune checkpoint strategies in non-small cell lung cancer (NSCLC).
First Author: Aakash Desai
Poster
2023 ASCO Annual Meeting
ARC-10: A phase 3 study to evaluate zimberelimab + domvanalimab versus pembrolizumab in front-line, PD-L1-high, locally advanced or metastatic non–small-cell lung cancer.
First Author: Christos Chouaid